SCIMP is a spatiotemporal transmembrane scaffold for Erk1/2 to direct pro-inflammatory signaling in TLR-activated macrophages.
SCIMP
Toll-like receptor
c-Fos
cytokine
extracellular-signal-regulated kinase
inflammation
innate immunity
macrophage
scaffold
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
07 09 2021
07 09 2021
Historique:
received:
15
03
2021
revised:
12
07
2021
accepted:
13
08
2021
entrez:
8
9
2021
pubmed:
9
9
2021
medline:
15
2
2022
Statut:
ppublish
Résumé
Immune cells are armed with Toll-like receptors (TLRs) for sensing and responding to pathogens and other danger cues. The role of extracellular-signal-regulated kinases 1/2 (Erk1/2) in TLR signaling remains enigmatic, with both pro- and anti-inflammatory functions described. We reveal here that the immune-specific transmembrane adaptor SCIMP is a direct scaffold for Erk1/2 in TLR pathways, with high-resolution, live-cell imaging revealing that SCIMP guides the spatial and temporal recruitment of Erk2 to membrane ruffles and macropinosomes for pro-inflammatory TLR4 signaling. SCIMP-deficient mice display defects in Erk1/2 recruitment to TLR4, c-Fos activation, and pro-inflammatory cytokine production, with these effects being phenocopied by Erk1/2 signaling inhibition. Our findings thus delineate a selective role for SCIMP as a key scaffold for the membrane recruitment of Erk1/2 kinase to initiate TLR-mediated pro-inflammatory responses in macrophages.
Identifiants
pubmed: 34496234
pii: S2211-1247(21)01106-2
doi: 10.1016/j.celrep.2021.109662
pii:
doi:
Substances chimiques
Cytokines
0
Toll-Like Receptor 4
0
Toll-Like Receptors
0
Mitogen-Activated Protein Kinase 3
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109662Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests. K.S. is a co-inventor on patent applications for NLRP3 inhibitors, which have been licensed to Inflazome, Ltd., a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease. K.S. served on the Scientific Advisory Board of Inflazome in 2016–2017 and consults for Quench Bio USA and Novartis Switzerland.